Clinical Trials Logo

Tuberculosis clinical trials

View clinical trials related to Tuberculosis.

Filter by:

NCT ID: NCT03794284 Completed - Tuberculosis Clinical Trials

Multiplex PCR -Microarray-based Assay in the Detection of Mycobacterium

Start date: February 28, 2019
Phase:
Study type: Observational

The study will use the VereMTB tool for rapid diagnosis of TB or non-tuberculous mycobacterium (NTM) pulmonary infections in hospitalised patients, with positive results in acid-fast bacilli smears, which are emerging in many regions of the world.

NCT ID: NCT03787914 Completed - Tuberculosis Clinical Trials

Effect of Community Mobile Outreach Approach Compared to Facility Based Directly Observed Treatment Short Course on Treatment Outcome Among Tuberculosis Patients in Jeddah: A Randomized Controlled Trial

Start date: November 1, 2017
Phase: N/A
Study type: Interventional

To compare the effectiveness of the community mobile outreach approach in improving treatment outcomes (success rate) among tuberculosis patients with those being treated with facility based directly observed treatment short course (DOTS) in Jeddah region.

NCT ID: NCT03776500 Completed - Clinical trials for Tuberculosis, Pulmonary

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PBTZ169 in Multiple Dosing

Start date: February 21, 2019
Phase: Phase 1
Study type: Interventional

This is a randomized, double-blind, placebo-controlled, multiple ascending dose study conducted at one study center in Switzerland. Four (4) panels (A, B, C and D) of 8 male subjects (6 active and 2 placebo) each receiving multiple doses of PBTZ169 or a matching placebo, at increasing dose levels, once or twice daily. Subjects will participate in only one panel. Blocks of 4 subjects (3 under active treatment, 1 under placebo) will be investigated in parallel. Panels will start sequentially. Safety will be assessed throughout the study; serial ECGs and serial blood samples will be collected for the safety and PK assessment of PBTZ169. Dose escalation will be allowed once the Trial Safety Board has determined that adequate safety and tolerability after each panel completion has been demonstrated to permit proceeding to the next panel. In addition, a preliminary assessment of the drug interaction potential of PBTZ169 will be done by the measurement of inhibition or induction of human cytochromes through the metabolism of microdoses of standard probe substrates

NCT ID: NCT03767946 Completed - Tuberculosis Clinical Trials

Epidemiological Study In Tuberculosis-Endemic Urban Area in Senegal

MTBVAC-EPI
Start date: July 27, 2018
Phase:
Study type: Observational

A cross-sectional childhood M. tuberculosis infection survey of age-specific rates (defined by positivity to the test QuantiFERON-TB Gold Plus) will be conducted in Senegal to collect information on the local TB endemic to inform site selection, sample size, and recruitment strategies for a future efficacy trial of vaccine candidate MTBVAC in young children.

NCT ID: NCT03758612 Completed - Tuberculosis Clinical Trials

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults

Start date: January 16, 2019
Phase: Phase 1
Study type: Interventional

Partially-Blinded, Placebo-Controlled, Randomized, Single Ascending Dose (SAD) with a Food Effect Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults.

NCT ID: NCT03736278 Completed - Tuberculosis Clinical Trials

Characteristics of Tuberculosis Infection in Rheumatic Disease

Start date: November 10, 2018
Phase:
Study type: Observational

A retrospective study evaluating the characteristics of tuberculosis infection in patients of rheumatic disease.

NCT ID: NCT03734172 Completed - Tuberculosis Clinical Trials

Rapid and Accurate Diagnosis of Paediatric TB (RaPaed-AIDA-TB)

RaPaed
Start date: January 21, 2019
Phase:
Study type: Observational

This study will serve as a platform to evaluate new diagnostics in children suspected to have TB, establish diagnostic performance (sensitivity and specificity) and calculate positive and negative predictive values in a real-life cohort. Finally, this study will comprise the results of several tests in its database. This will allow simulation of diagnostic algorithms, that may be composed of screening (i.e. rule-out) tests together with confirmatory tests to maximize sensitivity and specificity.

NCT ID: NCT03728725 Completed - Clinical trials for Tuberculosis, Pulmonary

Xpert MTB/XDR Clinical Evaluation Trial

Start date: July 11, 2019
Phase:
Study type: Observational

FIND and partners intend to address the need for a multi- and extensively drug-resistant tuberculosis (M/XDR-TB) diagnostic solution for patients in settings with a high burden of drug-resistant tuberculosis (DR-TB) though the development, evaluation and introduction of an Xpert MTB/XDR assay

NCT ID: NCT03712709 Completed - Clinical trials for Tuberculosis, Pulmonary

Clinical Evaluation of the Truenat Point-of-care Tuberculosis Diagnostic Test

Start date: March 12, 2019
Phase:
Study type: Observational

Consenting adults presenting with signs and symptoms compatible with pulmonary tuberculosis will be interviewed for demographic and medical information, and then will be asked to provide 3-4 expectorated sputum specimens. In the study laboratory, sputa will be tested using conventional and investigational diagnostic tests for tuberculosis and rifampin resistance.

NCT ID: NCT03711721 Completed - Clinical trials for HIV and Tuberculosis Co-infection

Nutritional Support for HIV-Tuberculosis Co-infected Adults in Senegal, West Africa

Start date: June 2016
Phase: N/A
Study type: Interventional

Food insecurity can contribute to poor adherence to both tuberculosis treatment and antiretroviral therapy (ART). Interventions that target food insecurity have the potential to improve treatment adherence and decrease mortality. The goals of this study were to determine the cost, feasibility, acceptability, and potential impact of implementing nutritional support to improve adherence and treatment completion among HIV-TB co-infected adults in the Casamance region of Senegal, West Africa.